Palo Alto, California 94306


Purpose:

This is a 12-week, open-label, dose-escalation Phase 1b study of a herbal treatment given orally to subjects with ulcerative colitis. Subjects will be sequentially enrolled to one of two cohorts in up to two clinical sites. Treatment will be given for 8 weeks and study duration will be 12 weeks.


Criteria:

1. Age ≥ 18 years and ≤ 75 years. 2. Mild-to-moderate ulcerative colitis (biopsy-proven). 3. Mayo Scoring System Assessment of Ulcerative Colitis Activity score of 3 to 10 at screening. 4. Patients with active disease who are refractory to, intolerant to, or unwilling to take 5-aminosalicylic acid (5-ASA). 5. Physician's Global Assessment (PGA) Mayo subscore of at least 1 at screening. 6. Mayo rectal bleeding subscore of at least 1 at screening. 7. Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy with Mayo mucosal appearance subscore of at least 1 at screening. 8. Female patients of child-bearing potential must have a negative serum pregnancy test at the screening visit and agree to use two medically reliable methods of contraception (such as barrier with either spermicide or hormonal contraception) during the study period. 9. Male patients must be willing to use acceptable contraceptive methods and assure that their female partners of child-bearing potential use acceptable contraceptive methods during the study period. 10. Ability to adhere to the study visit schedule and other protocol requirements. 11. Adequate cardiac, renal, and hepatic function as determined by the principal investigators. 12. Written informed consent will be obtained before any study procedure is performed. Exclusion Criteria: 1. Are nursing or pregnant. 2. Patients who are in critical condition 3. Crohn's disease or indeterminate colitis. 4. Known sensitivity to any ingredients in the study drug. 5. A change in therapy within 2 weeks before the baseline visit. 6. Use of immunomodulators (cyclosporine, mercaptopurine, azathioprine, etc.). 7. Diagnosis of diabetes, heart failure, unstable angina, liver or kidney disease, or any other unstable medical condition. 8. Any clinically meaningful laboratory abnormality that in the judgment of the investigator should preclude participation in the study. 9. Impaired renal function (serum creatinine levels >2.0 mg/dL) at screening. 10. Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values >1.5 times upper limit of normal at screening. 11. Diagnosis of Clostridium difficile, Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic E. coli in stool. 12. Positive test for hepatitis C virus (HCV) antibody or hepatitis B surface antigen (HBsAg) at screening. 13. Active malignancy (except basal cell carcinoma). 14. Active alcohol or drug abuse. 15. Tobacco smoking within 2 weeks before study entry.


NCT ID:

NCT02442960


Primary Contact:

Principal Investigator
Berkeley Limketkai, MD
Stanford University

Ali Al-Rajhi, Ph.D.
Phone: 650 721 4284
Email: alrajhi@stanford.edu


Backup Contact:

N/A


Location Contact:

Palo Alto, California 94306
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 21, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.